Barclays analyst Peter Lawson maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a price target of $63.00. The company’s shares closed yesterday at $46.84.
According to TipRanks, Lawson is a 4-star analyst with an average return of 5.7% and a 44.19% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Exelixis, and Fate Therapeutics.
Springworks Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $64.80.
SWTX market cap is currently $3.45B and has a P/E ratio of -9.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Springworks Therapeutics (SWTX) Company Description:
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm’s products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
Read More on SWTX:
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
- SpringWorks Therapeutics price target raised to $74 from $73 at JPMorgan
- SpringWorks Therapeutics submits rolling NDA to FDA for mirdametinib
- SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
